The global skin cancer diagnostics market size is anticipated to reach USD 13.23 billion by 2030 and is expected to expand at a CAGR of 5.52% from 2024 to 2030. The skin cancer diagnostics market is driven by several key factors. Rising skin cancer incidence due to increased UV exposure and aging populations is a primary driver. Advances in diagnostic technologies, such as AI-powered imaging and molecular diagnostics, enhance accuracy and early detection, further propelling market growth. Increased awareness campaigns and government initiatives promoting early screening also contribute significantly. In addition, higher healthcare expenditures and improved access to dermatological care are crucial in expanding the skin cancer diagnostics market.
Over the past decade, significant advancements have been made in approaches to melanoma detection, all aimed at reducing the growing incidence of melanoma and its mortality rate. While these advancements have been well-documented to increase early melanoma detection, there has been considerable criticism of their efficacy in improving survival rates. Traditional methods for detecting skin cancer often involve time-consuming and expensive procedures, such as PET and CT scans, as well as invasive technologies using higher frequencies.
A biosensor developed at Queen Mary University of London in April 2024 offers a noninvasive and highly efficient solution. This biosensor leverages the unique properties of THz waves, which have lower energy than X-rays and are safe for humans, to detect subtle changes in cell characteristics. In addition, scientists have developed genomic tests that provide oncologists and dermatologists with valuable information about the molecular biology of tumors, particularly in patients with aggressive skin cancers such as invasive melanomas and high-risk Squamous Cell Carcinomas (SCCs). These tests analyze genetic information from a patient's primary tumor, helping physicians better forecast the likelihood of cancer recurrence after treatment and its potential spread to other parts of the body. Furthermore, these tests offer greater patient-specific insights that are not available through traditional cancer staging, which typically uses clinical information and lab reports compared with population-based data to determine a patient's prognosis.
In the era of COVID-19, teledermatology has become increasingly popular. These emerging techniques for skin cancer diagnosis have the potential to be integrated into teledermatology in primary care settings. Furthermore, combining AI with these emerging techniques can further enhance their widespread use. More large-scale, multicenter, prospective clinical trials are needed to prevent these emerging techniques from remaining experimental equipment used in only a few special centers. This can be achieved by maintaining interest in this issue among health providers, the general population, patients, and health-related organizations in each country.
Over the past decade, significant advancements have been made in approaches to melanoma detection, all aimed at reducing the growing incidence of melanoma and its mortality rate. While these advancements have been well-documented to increase early melanoma detection, there has been considerable criticism of their efficacy in improving survival rates. Traditional methods for detecting skin cancer often involve time-consuming and expensive procedures, such as PET and CT scans, as well as invasive technologies using higher frequencies.
A biosensor developed at Queen Mary University of London in April 2024 offers a noninvasive and highly efficient solution. This biosensor leverages the unique properties of THz waves, which have lower energy than X-rays and are safe for humans, to detect subtle changes in cell characteristics. In addition, scientists have developed genomic tests that provide oncologists and dermatologists with valuable information about the molecular biology of tumors, particularly in patients with aggressive skin cancers such as invasive melanomas and high-risk Squamous Cell Carcinomas (SCCs). These tests analyze genetic information from a patient's primary tumor, helping physicians better forecast the likelihood of cancer recurrence after treatment and its potential spread to other parts of the body. Furthermore, these tests offer greater patient-specific insights that are not available through traditional cancer staging, which typically uses clinical information and lab reports compared with population-based data to determine a patient's prognosis.
In the era of COVID-19, teledermatology has become increasingly popular. These emerging techniques for skin cancer diagnosis have the potential to be integrated into teledermatology in primary care settings. Furthermore, combining AI with these emerging techniques can further enhance their widespread use. More large-scale, multicenter, prospective clinical trials are needed to prevent these emerging techniques from remaining experimental equipment used in only a few special centers. This can be achieved by maintaining interest in this issue among health providers, the general population, patients, and health-related organizations in each country.
Skin Cancer Diagnostics Market Report Highlights
- Nonmelanoma dominated the cancer type segment and is anticipated to grow at fastest growth rate over the forecast period owing to the owing to the rising incidence of Nonmelanoma Skin Cancer (NMSC) and development of novel diagnostics tools for the diagnosis of no melanoma cancer
- Skin biopsy dominated the test type segment. Skin biopsies are pivotal in skin cancer diagnostics, serving as the gold standard for definitive diagnosis. Market driving factors include the rising prevalence, advancements in biopsy techniques, and improved pathological analysis. Increased awareness and screening programs promote early detection, boosting biopsy demand
- Imaging segment is expected to grow at faster rate during the review period. Factors such as the rising incidence of skin cancer, technological advancements in imaging modalities (like dermoscopy, optical coherence tomography, and reflectance confocal microscopy), and increasing awareness about early detection contribute to market expansion. Additionally, the growing adoption of non-invasive imaging techniques, which offer improved accuracy and reduced patient discomfort, further propel market growth
- Hospitals and clinics segment dominated the end-use segment and is anticipated to grow at fastest growth rate over the forecast period. As diagnostics are being increasingly adopted, their acceptance has increased in hospitals as well. Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals are aiming to provide a wide range of services in their settings
- North America dominated the skin cancer diagnostics market owing to factors such as the presence of major key players, favorable government initiatives for the development of innovative diagnostics tools
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope
Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis
Chapter 6. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis
Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type and End-use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Castle Bioscience
- DermTech
- bioMérieux , Inc.
- FOUNDATION MEDICINE, INC.
- DermaSensor, Inc.
- F. Hoffmann-La Roche Ltd
- NeoGenomics Laboratories
- Quest Diagnostics Incorporated
- SkylineDx
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | June 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 9.14 Billion |
| Forecasted Market Value ( USD | $ 13.23 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
